Search

The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

… Thursday, December 6, 2012 Summary The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research. The Geoffrey Beene Foundation is featuring six Memorial Sloan Kettering researchers in its current

Discover how Memorial Sloan Kettering is teaming up with local hospitals to promote healthy eating in diverse communities.

… Monday, October 4, 2021 Update: On June 16, 2022 Dr. Gany and her team published the results of a groundbreaking study, the first of its kind, in the  Journal of Clinical Oncology .  After six months of study enrollment, researchers found that patients who received a debit card for groceries and had

Descubre cómo Memorial Sloan Kettering se está uniendo a hospitales locales para promover la alimentación saludable en la comunidad latina.

… Monday, October 4, 2021 Se sabe que una dieta saludable ayuda a prevenir el cáncer. Pero una dieta saludable también es fundamental después de diagnosticar a los pacientes. Los tratamientos contra el cáncer pueden quitar el apetito a los pacientes. Sin embargo, deben alimentarse bien para estar lo suficientemente

The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and provide engaging broadcast and on-demand presentations of the latest cutting-edge oncology research. ASCO 2021 will focus on Equity: Every Patient. Every Day. Everywhere.

… Wednesday, June 2, 2021 Thousands of oncology experts from around the world will tune in from June 4 to June 8 for the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting . The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and

Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.

… Sunday, June 5, 2022 Some members of the MSK team behind the groundbreaking research at the American Society of Clinical Oncology, June 2022 (l to r): Dr. Luis Diaz, Dr. Andrea Cercek, Jenna Sinopoli, clinical trials nurse, Jill Weiss, clinical research supervisor, Melissa Lumish, clinical fellow. Some

Researchers have found that the genetic changes that cause pediatric leukemia are different from those that lead to leukemia in adults.

… Monday, February 18, 2019 Summary The finding that the mutations behind certain pediatric blood cancers are different from those that trigger leukemia in adults helps explain why some leukemias in children are so difficult to treat. A study exploring the genetic landscape of leukemia in children has

MSK employees celebrate the 2020 African American Day Parade with a watch party.

… Wednesday, January 1, 2020 Julia Ramirez was looking at her computer screen with tears in her eyes, and her 6-year-old son, Teo, wanted to know why. She tried to explain the deep emotions welling up as she viewed this year’s African American Day Parade at a Zoom watch party with her Memorial Sloan Kettering

New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.

… Thursday, November 20, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing

Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.

… Thursday, September 6, 2012 Summary Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms. Memorial Sloan Kettering researchers have discovered why a class of drugs called JAK2 inhibitors has not been

This three-part series summarizes MSK’s recent advances in clinical research and novel treatment approaches for rare head and neck cancers.

… Friday, March 22, 2024 Part 1: Rare Salivary Cancers Memorial Sloan Kettering Cancer Center (MSK) has a comprehensive and integrated head and neck cancer program with dedicated resources and specialists who treat patients with rare salivary, thyroid, non-melanoma skin, and oral cavity cancers. Clinical